Adult
Nystatin
Standard dose
100,000 units/mL oral suspension 1mL qds. Continue treatment for a further 2 days after lesions have healed
Renal and hepatic impairment
Renal impairment
No dose adjustment
Hepatic impairment
No information available for use in hepatic impairment.
Pregnancy and breastfeeding
Pregnancy
Safe to use
Breastfeeding
Safe to use
Additional information
- Nystatin should be kept in contact with the affected areas as long as possible before swallowing.
References
- Sandoz Limited. Summary of Product Characteristics. Nystatin Oral Suspension BP. Last revision of the text 29/7/2020. Accessed via https://www.medicines.org.uk/emc/product/4463/smpc#gref on 24/2/25
- The Renal Drug Database. Nystatin. Accessed via renaldrugdatabase.com on 24/2/25.
- BNF online accessed via www.medicinescomplete.com on 24/2/25
- Drugs and Lactation Database (LactMed). Nystatin monograph. Accessed at https://www.ncbi.nlm.nih.gov/books/NBK501922/ on 24/2/25.